Literature DB >> 24556353

Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.

Markus M Rinschen1, Bernhard Schermer2, Thomas Benzing3.   

Abstract

Blockade of the vasopressin-2 receptor (V2R) in the kidney has recently emerged as a promising therapeutic strategy in autosomal dominant polycystic kidney disease. The pathophysiologic basis of V2R-dependent cyst proliferation and disease progression, however, is not fully understood. Recent evidence suggests that polycystic kidney disease is characterized by defects in urinary concentrating mechanisms and subsequent deregulation of vasopressin excretion by the neurohypophysis. On the cellular level, several recent studies revealed unexpected crosstalk of signaling pathways downstream of V2R activation in the kidney epithelium. This review summarizes some of the unexpected roles of V2R signaling and suggests that vasopressin signaling itself may contribute crucially to loss of polarity and enhanced proliferation in cystic kidney epithelium.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Keywords:  ADPKD; Cell & Transport Physiology; Cell Signaling; collecting ducts; vasopressin

Mesh:

Substances:

Year:  2014        PMID: 24556353      PMCID: PMC4033383          DOI: 10.1681/ASN.2013101037

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  77 in total

1.  Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells.

Authors:  Markus M Rinschen; Ming-Jiun Yu; Guanghui Wang; Emily S Boja; Jason D Hoffert; Trairak Pisitkun; Mark A Knepper
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-05       Impact factor: 11.205

2.  Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

Authors:  Andreas L Serra; Diane Poster; Andreas D Kistler; Fabienne Krauer; Shagun Raina; James Young; Katharina M Rentsch; Katharina S Spanaus; Oliver Senn; Paulus Kristanto; Hans Scheffel; Dominik Weishaupt; Rudolf P Wüthrich
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

3.  Everolimus in patients with autosomal dominant polycystic kidney disease.

Authors:  Gerd Walz; Klemens Budde; Marwan Mannaa; Jens Nürnberger; Christoph Wanner; Claudia Sommerer; Ulrich Kunzendorf; Bernhard Banas; Walter H Hörl; Nicholas Obermüller; Wolfgang Arns; Hermann Pavenstädt; Jens Gaedeke; Martin Büchert; Christoph May; Harald Gschaidmeier; Stefan Kramer; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

4.  Epac regulates UT-A1 to increase urea transport in inner medullary collecting ducts.

Authors:  Yanhua Wang; Janet D Klein; Mitsi A Blount; Christopher F Martin; Kimilia J Kent; Vladimir Pech; Susan M Wall; Jeff M Sands
Journal:  J Am Soc Nephrol       Date:  2009-08-06       Impact factor: 10.121

5.  Quantitative phosphoproteomic analysis reveals cAMP/vasopressin-dependent signaling pathways in native renal thick ascending limb cells.

Authors:  Ruwan Gunaratne; Drew W W Braucht; Markus M Rinschen; Chung-Lin Chou; Jason D Hoffert; Trairak Pisitkun; Mark A Knepper
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

6.  Akt and ERK1/2 pathways are components of the vasopressin signaling network in rat native IMCD.

Authors:  Trairak Pisitkun; Vinitha Jacob; Stephen M Schleicher; Chung-Lin Chou; Ming-Jiun Yu; Mark A Knepper
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

7.  AVP-stimulated nucleotide secretion in perfused mouse medullary thick ascending limb and cortical collecting duct.

Authors:  Elvin Odgaard; Helle A Praetorius; Jens Leipziger
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-10

8.  GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity.

Authors:  Reena Rao; Satish Patel; Chuanming Hao; James Woodgett; Raymond Harris
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

9.  Phosphoproteomic profiling reveals vasopressin-regulated phosphorylation sites in collecting duct.

Authors:  Amar D Bansal; Jason D Hoffert; Trairak Pisitkun; Shelly Hwang; Chung-Lin Chou; Emily S Boja; Guanghui Wang; Mark A Knepper
Journal:  J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 10.121

10.  Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.

Authors:  Gianfranco Distefano; Manila Boca; Isaline Rowe; Claas Wodarczyk; Li Ma; Klaus B Piontek; Gregory G Germino; Pier Paolo Pandolfi; Alessandra Boletta
Journal:  Mol Cell Biol       Date:  2009-03-02       Impact factor: 4.272

View more
  13 in total

Review 1.  Vasopressin receptor antagonists.

Authors:  Biff F Palmer
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

2.  Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Authors:  Olivier Devuyst; Arlene B Chapman; Ron T Gansevoort; Eiji Higashihara; Ronald D Perrone; Vicente E Torres; Jaime D Blais; Wen Zhou; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

3.  Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Authors:  Ron T Gansevoort; Maatje D A van Gastel; Arlene B Chapman; Jaime D Blais; Frank S Czerwiec; Eiji Higashihara; Jennifer Lee; John Ouyang; Ronald D Perrone; Katrin Stade; Vicente E Torres; Olivier Devuyst
Journal:  Kidney Int       Date:  2019-03-09       Impact factor: 10.612

4.  N-Degradomic Analysis Reveals a Proteolytic Network Processing the Podocyte Cytoskeleton.

Authors:  Markus M Rinschen; Ann-Kathrin Hoppe; Florian Grahammer; Martin Kann; Linus A Völker; Eva-Maria Schurek; Julie Binz; Martin Höhne; Fatih Demir; Milena Malisic; Tobias B Huber; Christine Kurschat; Jayachandran N Kizhakkedathu; Bernhard Schermer; Pitter F Huesgen; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2017-07-19       Impact factor: 10.121

5.  Vasopressin Increases Urinary Acidification via V1a Receptors in Collecting Duct Intercalated Cells.

Authors:  Torsten Giesecke; Nina Himmerkus; Jens Leipziger; Markus Bleich; Taka-Aki Koshimizu; Michael Fähling; Alina Smorodchenko; Julia Shpak; Carolin Knappe; Julian Isermann; Niklas Ayasse; Katsumasa Kawahara; Jan Schmoranzer; Niclas Gimber; Alexander Paliege; Sebastian Bachmann; Kerim Mutig
Journal:  J Am Soc Nephrol       Date:  2019-05-16       Impact factor: 10.121

Review 6.  Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?

Authors:  Peter Janssens; Caroline Weydert; Stephanie De Rechter; Karl Martin Wissing; Max Christoph Liebau; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2017-04-28       Impact factor: 3.714

7.  Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.

Authors:  Ester M Pereira; Anatália Labilloy; Megan L Eshbach; Ankita Roy; Arohan R Subramanya; Semiramis Monte; Guillaume Labilloy; Ora A Weisz
Journal:  Am J Physiol Renal Physiol       Date:  2016-09-28

Review 8.  New Insights into the Molecular Mechanisms Targeting Tubular Channels/Transporters in PKD Development.

Authors:  Ming Wu; Shengqiang Yu
Journal:  Kidney Dis (Basel)       Date:  2016-03-25

Review 9.  Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment.

Authors:  Rhubaniya Mahendran; Soo Kun Lim; Kien Chai Ong; Kek Heng Chua; Hwa Chia Chai
Journal:  Clin Exp Nephrol       Date:  2021-07-12       Impact factor: 2.801

10.  Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.

Authors:  Katelyn A McKenzie; Mirelle El Ters; Vicente E Torres; Peter C Harris; Arlene B Chapman; Michal Mrug; Frederic F Rahbari-Oskoui; Kyongtae Ty Bae; Douglas P Landsittel; William M Bennett; Alan S L Yu; Jonathan D Mahnken
Journal:  BMC Nephrol       Date:  2018-12-27       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.